State of Alaska Department of Revenue Buys 37,259 Shares of CVS Health Corporation $CVS

State of Alaska Department of Revenue grew its stake in CVS Health Corporation (NYSE:CVS) by 24.0% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 192,696 shares of the pharmacy operator’s stock after purchasing an additional 37,259 shares during the quarter. State of Alaska Department of Revenue’s holdings in CVS Health were worth $16,512,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Turtle Creek Wealth Advisors LLC boosted its stake in shares of CVS Health by 43.8% during the 3rd quarter. Turtle Creek Wealth Advisors LLC now owns 11,209 shares of the pharmacy operator’s stock valued at $960,000 after purchasing an additional 3,414 shares in the last quarter. WealthPlan Investment Management LLC boosted its position in shares of CVS Health by 76.0% during the third quarter. WealthPlan Investment Management LLC now owns 3,470 shares of the pharmacy operator’s stock valued at $297,000 after purchasing an additional 1,498 shares in the last quarter. Nvwm LLC boosted its position in shares of CVS Health by 12,778.8% during the third quarter. Nvwm LLC now owns 6,697 shares of the pharmacy operator’s stock valued at $574,000 after purchasing an additional 6,645 shares in the last quarter. HBW Advisory Services LLC grew its stake in CVS Health by 3.5% in the third quarter. HBW Advisory Services LLC now owns 3,408 shares of the pharmacy operator’s stock worth $292,000 after purchasing an additional 115 shares during the period. Finally, Mather Group LLC. grew its stake in CVS Health by 41.2% in the third quarter. Mather Group LLC. now owns 14,807 shares of the pharmacy operator’s stock worth $1,269,000 after purchasing an additional 4,319 shares during the period. 80.66% of the stock is owned by hedge funds and other institutional investors.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Analyst commentary highlighted CVS’s stronger returns, improving earnings estimates and lower valuation relative to Alignment Healthcare, while pointing to progress in Aetna’s turnaround. CVS vs. ALHC: Which Medicare Advantage Stock Is the Better Pick Now?
• Positive Sentiment: CVS opened its first pharmacy-focused location in the Boston area, aimed at improving access to medications, immunizations and pharmacy services in an underserved community. CVS Pharmacy Celebrates Opening of First Pharmacy-Focused Location in Boston Area
• Positive Sentiment: MinuteClinic received its seventh consecutive Joint Commission accreditation, supporting CVS’s strategy to expand primary-care services across its retail health network. MinuteClinic earns seventh consecutive Joint Commission accreditation
• Neutral Sentiment: CVS announced programs promoting at-home heart-rhythm monitoring through Signify Health and women’s midlife health research through The Midlife Collective. These initiatives could support long-term engagement but are unlikely to materially affect near-term earnings. CVS Health – Early Detection Matters
• Negative Sentiment: CVS agreed to pay $315 million to settle Justice Department allegations that its pharmacies improperly filled controlled-substance prescriptions and submitted false claims to federal healthcare programs. CVS admitted no wrongdoing and disputed the allegations, but the agreement includes enhanced prescription oversight and creates a reputational and compliance overhang. CVS Agrees to Pay $315M for Opioid Prescription Allegations

CVS Health Stock Up 1.9%

Shares of NYSE:CVS traded up $1.75 on Thursday, hitting $92.14. 4,085,078 shares of the company traded hands, compared to its average volume of 8,330,671. The stock has a 50 day simple moving average of $91.88 and a 200-day simple moving average of $92.87. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74. The company has a market cap of $117.85 billion, a PE ratio of 24.38, a PEG ratio of 0.82 and a beta of 0.60. CVS Health Corporation has a 52 week low of $69.51 and a 52 week high of $110.68.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.87 by $0.71. The company had revenue of $106.10 billion for the quarter, compared to analysts’ expectations of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. CVS Health’s revenue was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, research analysts expect that CVS Health Corporation will post 8.02 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Thursday, October 22nd will be issued a dividend of $0.6650 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Thursday, October 22nd. CVS Health’s dividend payout ratio (DPR) is presently 70.37%.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Truist Financial raised their price objective on CVS Health from $108.00 to $118.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CVS Health in a research report on Friday, October 9th. Leerink Partners reduced their target price on shares of CVS Health from $119.00 to $112.00 and set an “outperform” rating on the stock in a research report on Monday. BMO Capital Markets set a $112.00 price target on shares of CVS Health in a research note on Wednesday, September 9th. Finally, JPMorgan Chase & Co. lifted their price target on shares of CVS Health from $111.00 to $118.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Twenty investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, CVS Health presently has an average rating of “Moderate Buy” and an average price target of $107.80.

CVS Health Company Profile

CVS Health Corp. is an integrated health care company that provides pharmacy, insurance and health services primarily in the United States. Its operations are designed to connect consumers, health plans, health care providers and pharmacy services across multiple points of care.

The company’s major businesses include CVS Pharmacy retail locations, prescription fulfillment and consumer health products; CVS Caremark, a pharmacy benefit management business; and Aetna, which offers health insurance products and related services for employers, individuals, government programs and other organizations.